Background: As 6% hydroxyethyl starch (HES) 130/0.40 or 130/0.42 can originate from different vegetable sources, they might have different clinical effects. The purpose of this prospective, randomized, double-blind controlled trial was to compare two balanced tetrastarch solutions, one maize-derived and one potato-derived, on perioperative blood loss in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Methods: We randomly assigned 118 patients undergoing elective cardiac surgery into two groups, to receive either a maize-or a potato-derived HES solution. Study fluids were administered perioperatively (including priming of CPB) until the second postoperative day (POD#2) using a goal directed algorithm. The primary outcome was calculated postoperative blood loss up to POD#2. Secondary outcomes included short-term incidence of acute kidney injury (AKI), and long-term effect (up to one yr) on renal function. Results: Preoperative and intraoperative characteristics of the subjects were similar between groups. Similar volumes of HES were administered (1950 ml [1250-2325] for maize-HES and 2000 ml [1500-2700] for potato-HES; P=0.204). Calculated blood loss (504 ml for maize-HES vs 530 ml for potato-HES; P=0.107) and the need for blood components were not different between groups. The incidence of AKI was similar in both groups (P=0.111). Plasma creatinine concentration and glomerular filtration rates did vary over time, although changes were minimal. Conclusions: Under our study conditions, HES 130/0.4 or 130/0.42 raw material did not have a significant influence on perioperative blood loss. Moreover, we did not find any effect of tetrastarch raw material composition on short and long-term renal function. Clinical trial registration: EudraCT number: 2011-005920-16.
Editor's key points
• The influence of hydroxyethyl starch (HES) raw material on haemostasis and renal outcome in cardiac surgery is unknown.
• Patients undergoing cardiac surgery with cardiopulmonary bypass were prospectively randomized to receive balanced tetrastarch solutions derived from either maize or potato.
• Perioperative blood loss, transfusion, and kidney injury did not differ between groups in this study of 118 subjects.
• These preliminary findings suggest no significant clinical differences between balanced tetrastarch solutions derived from two different sources.
Six percent hydroxyethyl starch (HES) 130/0.40 or 130/0.42, commonly known as tetrastarch, has been routinely used to treat hypovolaemia, in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), as it is considered to be superior for volume expansion compared with crystalloid solutions. 1 This fluid consists of large branched glucose molecules substituted with hydroxyethyl groups for increased solubility and intravascular persistence. They are formulated to a concentration of 6%, a mean molecular weight of 130 kDa, and a molar substitution of 0.40 or 0.42. There is an active debate over the use of tetrastarch in high risk surgical patients. However, five recent meta-analyses failed to identify an association between surgical HES administration and postoperative morbidity or mortality. [2] [3] [4] [5] [6] Newer tetrastarch solutions have been developed in an electrolyte balanced solution. Recent German guidelines recommend that if colloids are used in perioperative care, balanced solutions are preferred. 7 While previously published studies have shown that 0.9% NaCl ('unbalanced') HES solutions are associated with various clinical side-effects, balanced-HES solutions with electrolyte concentrations closer to human plasma have not been as rigorously examined. Interestingly, these newer solutions might improve postoperative acid-base status 8 and potentially decrease the incidence of AKI and use of renal replacement therapy (RRT). 9 Importantly, balanced tetrastarch solutions can be derived from two different raw materials (maize or potato). Maize and potato-derived HES differ in their molecular and chemical structures 10 and are not bioequivalent. 11 Maize starch is largely composed (98%) of highly branched amylopectin, while potato starch contains a lower degree of branching, consisting of a heterogeneous mixture of around 75% of amylopectin and 25% of linear chains of amylose. Potato starch contains several thousand esterified phosphate groups, whereas almost none can be detected in maize starch. Negatively charged phosphate-ester groups in potato-HES could impair coagulation and also metabolization in the liver. Jamnicki and colleagues 12 demonstrated that potato-HES compromises in vitro blood coagulation more than maize-HES. There is clinical evidence supporting the clinical use of maize-HES, while published data are lacking with regards to potato-HES. 13 Therefore, one cannot justify the clinical use of potato-HES with evidence derived from studies investigating maize-HES. The main objective of this prospective, randomized, double-blind trial was to compare two balanced tetrastarch solutions, one maize derived 6% HES 130/0.4 (Volulyte ® , Fresenius Kabi GmbH, Bad Homburg, Germany) and one potato derived 6% HES 130/0.42 (Vitafusal ® , Serum Werk Bernburg AG, Germany), on perioperative blood loss in patients undergoing cardiac surgery. Additionally, as the short and long-term safety profile of HES continues to fuel controversy, we secondarily examined both perioperative and long-term renal function, patient quality of life and occurrence of pruritus.
Methods

Ethics
The investigation was approved by the Ethics Committee of Brugmann's Hospital and registered under the EudraCT number: 2011-005920-16. All 118 subjects provided written informed consent the day before surgery.
Patients
Inclusion criteria were patients >18 yr undergoing elective cardiac surgery with CPB. Exclusion criteria were patients with an ASA physical status greater than III, heart failure (left ventricular ejection fraction <30%), cardiac arrhythmias, significant aortic regurgitation, coagulation disorders ( platelet count <100 000 µl −1 , activated partial thromboplastin time >1.5 normal), preoperative renal dysfunction (serum creatinine >2 mg ml
, oliguria, anuria, or receiving haemodialysis), impaired hepatic function (aspartate amino-transferase, alanine amino-transferase >2 times normal), current pregnancy or lactation, and known allergy to HES.
Randomization and blinding
Randomization of the study was created by our hospital pharmacist in blocks of 10 using an internet-based software (http://www. randomization.com). The morning of surgery, blinded solutions were provided in identical plastic bags (500 ml) which prevented identification of the type of fluid being used. All investigators and people taking care of the patients remained blinded until the completion of the study and finalization of the statistical analysis.
Anaesthesia procedures
Premedication was standardized and consisted of 0.5 mg of alprazolam on the morning of surgery. Preoperative medications such as β-blockers, statins and calcium channel blockers were continued until the day of surgery. Preoperative antiplatelet drugs were stopped seven days before surgery, unless medical conditions required them to be maintained until the day of surgery. Angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) and oral hypoglycaemic agents were stopped 24 to 48 h before surgery. Standard monitoring included 5-lead ECG, pulse oximetry, noninvasive blood pressure, central venous pressure, invasive radial artery catheter (using a Flotrac catheter connected to the Vigileo monitoring device, Edwards Lifesciences, Irvine, CA, USA), rectal temperature, inspiratory and expiratory gas concentrations, urine output, and depth of anaesthesia monitoring (Spectral Entropy, GE Healthcare, Helsinki, Finland). Anaesthesia was induced with lean body weight-adjusted doses of etomidate (0.2 mg kg ) using a target-controlled infusion pump (Alaris ® PK) syringe assessment. 14 were administered to all subjects. Anaesthetic drugs were adjusted intraoperatively to target a spectral entropy value between 50 and 60. Subjects were allowed to receive up to 500 ml of balanced crystalloid before CBP. The CPB circuit was primed exclusively with 150 ml of mannitol, 5000 i.v. of heparin and 1000 ml of the HES solution allocated to each subject, with the same CPB circuit was used in all subjects. Anticoagulation was achieved with heparin (400 IU kg
), and activated clotting time (ACT) was kept >600 sec during CPB with repeated boluses of heparin when required. Mild to moderate hypothermia was induced (32-34°C) depending on the surgical procedure. Pump flow rate was maintained around 2.8 Litre min −1 m −2 . Mean arterial pressure was kept between 50 and 70 mm Hg with phenylephrine boluses if required. Cold blood cardoplegia was used in all patients. In order to maintain the filling volume of the circuit, only the allocated study HES was added. All subjects were rewarmed to 35.5°C before weaning from CPB. Remaining heparin at the end of the CPB was neutralized with protamine sulfate at a ratio of heparin/protamine of 2:1. If necessary, additional protamine doses were administered to return the ACT value to baseline. The blood remaining in the CPB circuit was re-transfused without salvage processing after sternal closure. Insulin was administrated as a continuous infusion for blood glucose concentration >150 mg dl
. The trigger for transfusion of allogeneic red blood cells was a haemoglobin <7 g dl
during CPB and <8 g dl −1 after the end of surgery. Fresh frozen plasma, platelets, or fibrinogen were given in the presence of diffuse microvascular bleeding, associated with abnormal coagulation values (either prothrombin time or activated partial thromboplastin time >1.5 of the normal value, platelet count <100 000 µl
, respectively). All patients were performed on by three experienced senior cardiac anaesthetists and by the same two cardiac surgeons. After surgery, subjects were transferred to the ICU and controlled mechanical ventilation was maintained with the same ventilation settings used in the operating room. Postoperative sedation used either midazolam (1-3 mg h ), depending on the critical care physician taking care of the patient who was also blinded to the study fluids allocation. The trachea was extubated when subjects were haemodynamically stable, temperature >36°C, spontaneous respiration maintained with adequate blood gases, and no bleeding. Postoperative maintenance fluid was 5% dextrose -NaCl 0.45% (0.5 ml kg
). In addition to this maintenance fluid, a maximum daily dose of 50 ml kg −1 of study fluid was allowed. If additional volume was required and the maximum dose of HES was reached, 3% modified fluid gelatin (Geloplasma ® , Fresenius Kabi GmbH, Bad Homburg, Germany) or a crystalloid (normal saline 0.9%) was used, depending on physician preference. The decision for re-exploration for postoperative bleeding was made using our institution criteria: chest tube drainage ≥500 ml during the first h, ≥400 ml per h during the first 2 h, ≥300 ml per h during the first 3 h, ≥1000 ml during the first 4 h, ≥1200 ml during the first 5 h, 100 ml per h during the first 12 h and massive bleeding, cardiac tamponade, or sudden cardiac arrest in a bleeding patient.
Study fluid administration using a goal directed haemodynamic protocol
Perioperative study fluid administration was started immediately after induction of anaesthesia and was based on a goal-directed haemodynamic algorithm using stroke volume variation (SVV), to assess fluid responsiveness. This pre-defined algorithm allowed us to standardize study fluid administration and use of vasopressors and inotrope agents consistently in all subjects (Fig. 1) . Study fluids were titrated as 250 ml boluses up until POD#2 to maintain SVV (during mechanical ventilation) less than 13% 15 (Vigileo, Edwards LifeSciences, Irvine, USA). After extubation, fluid administration was at the discretion of the critical care provider.
Outcome variables
The primary outcome was defined as calculated blood loss from the time of surgery up to POD#2. Calculated blood loss was quantified using a formula taking into account preoperative and postoperative haematocrit and estimated blood volume. 16 Secondary outcomes were defined as short and long-term effects of study fluids on postoperative renal function. Short term renal function was assessed by quantifying the incidence of 1) AKI calculated using the Acute Kidney Injury Network (AKIN) classification (without taking into account urine output criteria) based on change in serum creatinine from preoperative baseline (day before surgery) to POD#2 17 and 2) requirement for the use of RRT.
For long-term assessment of renal function, medical records were examined using our hospital database (Mediview ® and Mediweb ® software) in order to record urea and creatinine measurements and the estimated glomerular filtration rate (eGFR) during outpatient postoperative follow-up appointments. The eGFR was calculated using the CKD -EPI formula. 18 When no results were found, the subjects' general practitioner and/or cardiologist were contacted by telephone in order to inquire about health, potential delayed complications, and to obtain the urea and creatinine measurements. The goal was to collect at least one value between discharge and six months postoperatively and one additional value at one yr postoperatively. Tertiary outcomes included exposure to blood products, transfusion rates, ICU and hospital LOS, incidence of postoperative complications and mortality. All laboratory and arterial blood gas parameters were measured and recorded at different time points. Subjects were also personally contacted in order to assess potential pruritus experiences during their postoperative period and their health-related quality of life. For this last quantification we used the MacNew questionnaire 19 20 which allowed us to assess how cardiac surgery impacted daily quality of life between one and two yr after surgery.
Power analysis
A sample size calculation was determined a priori based on our primary outcome using the results of our institution database (Rans D BJ, Van der Linden P Blood sparing effect and safety of tranexamic acid compared to aprotinin in adult cardiac surgery. Eur J Anaesth 2010; 27) which demonstrated that the average calculated blood losses from surgery up to POD#2 was 692±288 ml. For a type I error of 0.05 and a power of 0.08, 59 subjects per group were needed to detect a blood loss difference of 150 ml (at 100% of haematocrit, corresponding to one unit of packed red blood cell) between groups.
Statistical analysis
The distribution of continuous variables was assessed using a Kolmogorov-Smirnov test. Parameters not normally distributed were compared using a Mann-Whitney U-test and expressed as median [25%-75%] percentiles. Creatinine and glomerular filtration rate values were normally distributed. Linear mixed models 21 were used to model the relationship of log(creatinine) and glomerular filtration rate (GFR) ratio through time (from pre-operation until one yr postoperatively). A multiple imputation for multiple level data was conducted with the mice R package 22 23 for a missing at random process with 20 iterations, five imputed datasets and run linear mixed models on pooled data.
The best maximum likelihood model found incorporates the following fixed effects: time, group, fluid balance at 48 h and an intervention effect. Data were expressed as mean (). Discrete variables were compared using a χ 2 test and expressed as percentages. Significance was set at P<0.05.
Results
A total of 227 patients were screened for eligibility from March 2012 until September 2014 and 118 patients were included and prospectively randomized between the two groups (Fig. 2) . Preoperative subject characteristics (Table 1 ) and intraoperative variables (Table 2 ) revealed no significant differences between groups. Similar volume of colloids were administered up to POD#2, but subjects in the Potato HES group received significantly more crystalloids (Table 3 ). Regarding our outcome variables (Table 3) , calculated blood loss until POD#2 was similar in both groups as well as the cumulative measured 48 h blood loss. Transfusion of blood products ( packed red blood cells, fresh frozen plasma, platelets) was also comparable between groups. With respect to relevant postoperative complications, atrial fibrillation occurred in 26% of subjects with no difference between groups (Table 3) . Four patients (3.4%) needed surgical reexploration for postoperative bleeding: three in the potatogroup and one in the maize-group. With regard to mechanical ventilation time, ICU and hospital LOS, no significant differences were observed between groups. Eight deaths occurred after the long-term follow-up (four in each group), all of which were not considered to be related to the study fluids. The incidence of AKI (14%) at POD#2 was comparable in both groups. Three patients required RRT during the postoperative ICU period: two in the maize group and one in the potato group. Of the 118 subjects included in the study, 91 had follow-up renal laboratory results recorded up to at least 360 days after surgery. Plasma creatinine concentration and glomerular filtration rate (GFR) varied over time, although these variations appear to be minimal and were not different between groups (Table 4) . Two factors that were associated with a decrease in these two parameters were a positive fluid balance at POD#2 (P=0.003) and age (P<0.001). Regarding quality of life (Supplementary material, Appendix 1), 77 subjects answered the MacNew questionnaire in the postoperative period: 33 had received maize-HES and 44 had received potato-HES without significant difference between groups. The mean time for answering the questionnaire was 656 days after surgery. No subject described pruritus without being prompted during the postoperative period. Out of the 77 subjects who answered the question when specifically prompted about its occurrence, only 4 (5%) experienced pruritus during the postoperative period, two in each group. Finally, perioperative haemodynamic variables, laboratory values and blood gas measurements were similar between groups at multiple times points (data not shown). No patients in the current study presented any type of anaphylactic reaction after HES administration.
Discussion
No significant difference was found between the two balanced HES groups with regard to perioperative blood loss. This is in accordance with the only available study that compared the use of two balanced HES fluids from different vegetable sources in the perioperative setting. This study, published by Sethi and colleagues 24 compared a waxy maize-based HES solution with a potato starch-based HES solution, in patients undergoing coronary artery bypass grafting (CABG), with the aim to assess their effects on haemostasis (chest tube blood drainage, re-exploration rate, transfusion rate) and organ function. Importantly however, both HES solutions were only used to prime the CPB circuit (intraoperative use exclusively). Moreover, that study was not (14) 6 (10) [range], and quantitative data as double blinded and was performed in patients with a relatively low risk of bleeding (CABG only). Furthermore, they did not use a haemodynamic algorithm to guide fluid administration. Interestingly, the transfusion rate was relatively low in our trial (25%) compared with the literature (>50% [25] [26] [27] ). This finding is likely explained by the transfusion and fluid management algorithm we used in our trial, which has consistently been shown to improve postoperative outcome [28] [29] [30] [31] [32] and to decrease the amount of fluid given intraoperatively. 33 An important positive effect of less fluid administration is less haemodilution and, therefore, less blood product administration.
It is important to note that no algorithm was used to guide HES administration, in the vast majority of previous trials assessing HES utilization in cardiac surgery patients. 8 24 34 This point becomes even more important when considering the actual haemodynamic end-points used in these trials, which was typically a static variable such as central venous pressure (CVP). Unfortunately, CVP has clearly been demonstrated to be a weak predictor of fluid responsiveness 35 and could have confounded the results of these previous studies. In our study, the median amount of fluid administered up to POD#2 was ∼ 7000 ml (crystalloids and HES together). Much larger cumulative fluid administration, (up to 10-12 Litre in 24 h) was recently reported. 8 26 In these studies, no goal directed protocol was used to guide fluid administration. These findings further support the results of a recent survey that suggests that goal-directed fluid management is still poorly adopted in clinical practice. 36 Similar to the decreased fluid administration noted in our study, we observed a relatively low surgical re-exploration rate (3.4%) compared with the relevant literature. 8 24 This observation might also be related to the fact that our surgeons were present from skin incision to closure, after careful haemostasis of the surgical field. [37] [38] [39] [40] [41] and 2%-9% for RRT 34 37 42 ). Our results also confirm what has been published recently in a systematic review 2 and meta-analyses. 3 4 6 These authors reviewed the literature evaluating short term renal function after intraoperative administration of a tetrastarch solution compared with any other fluid type, in patients undergoing elective surgical procedures. They all demonstrated that no differences were noted between the use of a tetrastarch and any of the other tested fluids. It is important to realize that the follow-up period of the different review articles was too short to assess long-term adverse renal effects of HES. Therefore, our longer follow-up period of at least one yr after surgery, helps to address this issue by demonstrating that the choice of balanced HES fluid does not appear to impact longterm renal function. Plasma creatinine concentration and glomerular filtration rates did vary over time, although changes were minimal. The two factors significantly affecting these parameters were a positive fluid balance at POD#2 and age. The deleterious effect of perioperative fluid balance on postoperative renal function has been already reported. [43] [44] [45] Age has also been found to be a predictor for alteration of renal function in cardiac surgery. 46 We did not find any influence of either HES fluid on patient quality of life. We also found no difference of the fluid type on the occurrence of pruritus. The incidence of pruritus was 5% in our trial which is similar to another study 8 (4.6%), however the follow-up period was 60 days post-surgery which may be too short to adequately assess this issue.
Strengths and limitations
Strengths of this study indicate use of a pre-defined goal directed fluid algorithm perioperatively until extubation, and inclusion of multiple types of surgeries that required CPB, especially those with a high risk of bleeding (e.g. repeat surgery, combined surgery).
In most published studies, only low to moderate risk patients were included. 24 This is the first published study to assess the long-term (up to one yr after surgery) effects of HES administration on renal function, occurrence of pruritus and quality of life. In most surgical trials assessing the influence of HES on postoperative morbidity, study periods were quite short and ended before long-term adverse effects could be documented. Our study has several limitations. First, as the actual calculated blood loss difference between both HES types was only 26 ml (or a 4% effect size), our study was probably underpowered to demonstrate a significant difference in our primary outcome. Our study was also underpowered to detect differences in other complications, especially regarding renal function (AKI, RRT). The inclusion of significantly more subjects would have been necessary to effectively detect a difference. Additionally, the decision for starting RRT was not standardized in the study protocol and was instead based on clinician judgement. Similarly, the criteria for ICU and hospital discharge were not pre-defined and were instead determined based on clinical judgement. Hopefully, any resulting bias is limited by the prospective, randomized and double blinded study design we used.
Conclusions
Under our study conditions, the HES 130/0.4 or 130/0.42 raw material does not seem to have an influence on perioperative blood loss. Moreover, we did not find any long-term effect of tetrastarch raw material composition on short and long term renal function, occurrence of pruritus or quality of life.
